Indication
Severe Checkpoint Inhibitor Pneumonitis
1 clinical trial
2 products
Clinical trial
The Efficacy and Safety of Corticosteroids in Combination With Biological Agents in the Management of Severe Immune Related Adverse Events Cohort A: The Efficacy and Safety of Corticosteroids or Corticosteroids Combination With Ruxolitinib in Patients With Severe Checkpoint Inhibitor PneumoniaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
Corticosteroids